The limited screening value of insulin-like growth factor-i as a marker for alterations in body composition in very long-term adult survivors of childhood cancer by Blijdorp, K. (Karin) et al.
Pediatr Blood Cancer 2012;59:711–716
The Limited Screening Value of Insulin-Like Growth Factor-I as a Marker for
Alterations in Body Composition in Very Long-Term Adult Survivors of
Childhood Cancer
Karin Blijdorp, MD,1,2* Marry van den Heuvel-Eibrink, MD, PhD,1 Rob Pieters, MD, PhD,1 Annemieke Boot, MD, PhD,3
Johanna Sluimer, MLS,4 Aart-Jan van der Lelij, MD, PhD,2 and Sebastian Neggers, MD, PhD1,2
INTRODUCTION
Childhood cancer survival rates have improved significantly,
with 70–80% of patients becoming long-term survivors [1]. It has
been estimated that 1 out of 640 young adults in the U.S. is a
survivor of childhood cancer [2]. Consequently, the incidence of
late, treatment-related complications is increasing. Endocrine
sequelae, such as the metabolic syndrome, osteopenia, subfertility,
thyroid dysfunction, and growth hormone deficiency (GHD),
represent an important category of such late effects [3–8].
GHD, which has an incidence of 29–39% after CRT treatment
[9], has many effects on the metabolic system, such as decreased
lean body mass and impaired bone mineral density, increased
abdominal fat mass, dyslipidemia, insulin resistance, and subse-
quent raised cardiovascular morbidity later in life [5]. GHD, due
to damage of the radiosensitive hypothalamo-pituitary region by
CRT, has been associated with low IGF-I levels in adult childhood
cancer survivors [6,10]. However, it has been shown that IGF-I is
a poor marker for GHD in patients treated with CRT [11] and that
only very low levels of IGF-I are predictive of GHD [12].
In a previous study in 114 childhood acute lymphoblastic
leukemia (ALL) survivors that were treated with CNS irradiation,
it was shown that low IGF-I levels were associated with altered
body composition, represented by decreased lean body mass,
increased total fat percentage, and 65% more visceral fat in com-
bination with a worsened metabolic risk profile, represented by
insulin resistance, and dyslipidemia [13]. This study confirmed
results of earlier studies of CRT treated ALL survivors that
showed low IGF-I levels associated with total and visceral fat
percentage, but not with BMI [6,14]. However, most studies fo-
cused on relatively small groups of ALL survivors and after CRT
treatment. The value of IGF-I as a marker for body composition,
and its association with GHD, is uncertain. Therefore, in this
study we analyzed IGF-I levels in a single center cohort of 610
adult childhood cancer survivors.
PATIENTS AND METHODS
Patients
We performed a retrospective single center study. Follow-up at
our adult late effects outpatient clinic for long-term childhood
cancer survivors starts 5 years after cessation of therapy and
consultation is individualized, based on cancer diagnosis and
treatment protocol. Out of 885 adult childhood cancer survivors,
diagnosed and treated between 1964 and 2005, we identified and
included 610 survivors, in which IGF-I had been measured
between 2004 and 2009, at least 5 years after cessation of cancer
treatment. Twenty survivors were living abroad at the time of
follow-up, 21 refused to participate and 201 survivors did not
show up at the outpatient clinic, due to the fact that the late
effects clinic was a new setting and survivors could be under
treatment by another specialist. Up until 2009, IGF-I levels
were assessed based on former diagnosis and treatment as routine
follow-up screening for GHD. Thereafter, according to the nation-
al guidelines of screening for late effects as implemented in 2010
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by the Dutch Childhood Oncology Group (DCOG), routine
measurement of IGF-I levels was omitted.
Clinical Parameters
Data concerning treatment protocols, as well as disease and
patient characteristics, were retrieved from our local database and
completed from the medical records where necessary (Table I).
Follow-up time was defined as time between cessation of therapy
and the most recent visit. Follow-up data of the most recent visit
were evaluated including the following variables: use of medica-
tion, weight, height, target height (TH) calculated from the height
of the survivors’ parents [15], body mass index (BMI) calculated
from height and weight [16], and waist–hip ratio (WHR) as
measured by waist circumference divided by hip circumference
[17]. Final height standard deviation score (SDS) was calculated
using reference values for Dutch adults: a mean (SD) of 184.0
(7.1) cm for males and 170.6 (6.5) cm for females [15].
Body Composition
Data on total body fat mass (kg), lean body mass (kg), and
percentage of body fat were retrieved from dual energy X-ray
absorptiometry (DXA, Lunar Prodigy, GE Healthcare, Madison,
WI) (measured in 422 survivors) and assessed as previously de-
scribed, on the same day as IGF-I measurement. In addition,
visceral fat percentage was calculated from intra-abdominal fat
(kg) and total fat (kg) using the DXA scan [18]. Values for lean
body mass and total fat percentage were compared with normal
Dutch reference values and calculated as SDS [19]. WHR and
visceral fat percentage were not analyzed in the subset of survi-
vors treated with abdominal radiotherapy because of detrimental
local effects on body fat and the frequent occurrence of scoliosis.
Laboratory Assessments
IGF-I was assessed by Immulite 2000 (DPC Biermann GmbH/
Siemens, Fernwald, Germany), a solid-phase, enzyme-labeled
chemiluminescent immunometric assay, with an intra assay vari-
ability of 2–5%, and an inter assay variability of 3–7% [16]. IGF-I
levels were compared with reference values by using SDS [20]. In
cases where GHD was suspected (i.e., IGF-I below 2 SDS)
either insulin tolerance tests or, if contra-indications were present
(diabetes mellitus and heart failure), GHRH-Arginine tests were
performed [12]. However, only 28 out of the 85 survivors with an
IGF-I below 2 SDS were tested for GHD. Eight out of these 28
survivors were tested before 18 years of age because of growth
impairment during childhood. One possible reason that only a
proportion of the survivors with IGF-I below 2 SDS were tested
for GHD is that some endocrinologists are reluctant to treat
childhood cancer survivors with growth hormone because of the
resultant high recurrence rate [21].
Treatment Groups
Baseline characteristics of the included survivors are shown in
Table I. Three hundred and eighty one survivors had been treated
with chemotherapy only. Seventy-three subjects, mainly brain
tumor survivors, had been treated with cranial irradiation focused
on the tumor field (tumor field CRT). Fifty-seven subjects, mainly
leukemia survivors, had been treated with irradiation of the whole
cranium (CRT). Twenty survivors had received additional irradia-
tion of the spinal cord. In three leukemia survivors both cranial
irradiation and total body irradiation (TBI) were administered.
The following treatment groups were analyzed separately after
excluding survivors that were treated with growth hormone at the
time of the study (n ¼ 23): CRT treated leukemia survivors (25
Gy (24–25)), including 57 CRT survivors, plus three survivors
that had been treated with CRT and TBI, minus two subjects that
received GH therapy at follow-up (n ¼ 58); survivors treated with
local irradiation of the cranium (mainly brain tumors) (42 Gy
(35–54)) (n ¼ 56); and TBI survivors (8 Gy (8–12)) (n ¼ 21).
These three groups were compared separately with all other
survivors (n ¼ 452), hereafter, referred to as the not cranially
irradiated group.
Confounding Factors
Oral contraceptives can result in lower IGF-I levels, and
impaired thyroid function or impaired gonadal function can alter
body composition. No subjects were identified with untreated
hypothyroidism. Therefore, in our analysis we only adjusted for
hypogonadism, represented by oligo- or amenorrhea in women or
low testosterone levels in men (<9 nmol/L) and the use of oral
contraceptives in women. As previous therapy with corticoste-
roids may influence body composition, we also adjusted for
corticosteroid treatment.
Statistics
All data were expressed as median (interquartile range, IQR)
unless specified otherwise. Differences between treatment groups
were tested using the Mann–Whitney U-test for scaled data and
the Chi-squared test or the Fisher’s exact test for nominal data.
Correlations were tested using partial correlations. Regression
analysis was used to correct for possible confounding factors. If
no SD scores were available, body composition parameters were
adjusted for sex and age. P-values are all measured in the two-
way classification with P < 0.05 considered statistically signifi-
cant. Statistical analysis was performed using SPSS 17.0 software
(SPSS, Chicago, IL).
RESULTS
IGF-I Values
IGF-I SDS of the total group was 0.35 (range 5.55–2.55),
which indicates that IGF-I in this group of adult childhood cancer
survivors was lower compared to normal subjects. After correc-
tion for possible confounders, both cranially irradiated leukemia
survivors and brain tumor irradiated survivors had significantly
lower IGF-I SDS, as compared to those treated without cranial
irradiation (P < 0.001) (Table III). No significant difference in
IGF-I SDS was found when comparing the TBI/BMT group with
the not cranially irradiated group (P ¼ 0.06). Compared with not
irradiated survivors, the risk of having an IGF-I SDS below 1 is
4.3 times higher in CRT survivors and 3.2 times higher in survi-
vors treated with localized irradiation therapy for brain tumors
(OR 4.3 P < 0.001 and OR 3.2, P < 0.001).
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IGF-I and Growth Hormone Deficiency
Twenty-eight out of the 85 subjects with an IGF-I below 2
SDS were tested with a growth hormone stimulation test, as
described earlier (a GHRH-Arginine test was performed in 11
survivors). Seventeen patients were diagnosed with severe GHD
by growth hormone stimulation testing, defined as a GH peak
<3 mg/L (insulin tolerance test) or <9 mg/L (GHRH-Arginine
test) [22], whereas, 11 subjects did not have GHD. The 17
GHD subjects had a median IGF-I SDS of 4.6 (5.7; 2.3),
the 11 non-GHD subjects had a median IGF-I SDS of 3.8 (5.6;
2.7), (P ¼ 0.39).
Final Height and Body Composition
Raw data on height and body composition data of the total
cohort are depicted in Table II. Adjusted regression coefficients of
the different radiotherapy groups as compared to the not cranially
irradiated group are depicted in Table III, which is referred to in
the following section. Survivors treated with cranial irradiation
and irradiated brain tumor patients had significantly lower height
SDS (P < 0.001) and higher total fat percentage SDS
(P < 0.001). Leukemia survivors treated with cranial irradiation
had higher BMI (P < 0.001), higher WHR (P < 0.05), and
higher visceral fat percentage (P < 0.001) than those treated
without radiotherapy. Irradiated brain tumor survivors had a
higher total fat percentage and lower lean body mass, than those
treated without radiotherapy (P < 0.05 and P < 0.001, respec-
tively). Survivors treated with TBI had significantly lower height
SDS (P < 0.05), lower BMI (P < 0.05), and lower lean body
mass (P < 0.001). To correct for TH, the difference between
TH SDS and final height SDS was calculated. This was signifi-
cantly greater in all cranially irradiated groups compared to the
not cranially irradiated group (P < 0.001).
IGF-I and Body Composition
After correction for possible confounders, in the whole cohort,
IGF-I SDS was positively correlated with height SDS (r ¼ 0.23,
P < 0.001) and lean body mass SDS (r ¼ 0.15, P ¼ 0.01); IGF-I
SDS was inversely correlated with BMI (r ¼  0.12, P ¼ 0.04),
WHR (r ¼  0.15, P ¼ 0.01), and total fat percentage SDS
(r ¼  0.14, P ¼ 0.02). Visceral fat percentage, measured by
DXA, was not correlated with IGF-I (r ¼  0.1, P ¼ 0.1).
When analyzing only the subgroup that had been treated with
cranial irradiation (n ¼ 135), IGF-I SDS was positively correlated
with height SDS (r ¼ 0.24, P ¼ 0.02) and lean body mass
(r ¼ 0.23, P ¼ 0.03). IGF-I SDS was not significantly correlated
with BMI (r ¼  0.07, P ¼ 0.58), WHR (r ¼  0.1, P ¼ 0.37),
or total fat percentage (r ¼  0.07, P ¼ 0.51).
DISCUSSION
The value of IGF-I as a marker for body composition in long-
term childhood cancer survivors has not been studied extensively.
Here, we show significantly lower IGF-I SDS and altered body
composition in subgroups of survivors, that is, ALL survivors
treated with CRT and brain tumor survivors treated with local
irradiation. However, IGF-I and all measures of body composition
are so weakly correlated that the value of IGF-I as a marker for T
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clinically relevant alterations in body composition has to be con-
sidered insufficient.
In this study we assessed the value of IGF-I as a marker for
body composition and GHD. Several studies have shown that
IGF-I is the best marker for GH secretory status [23–25]. For
this reason, it was initially assumed that IGF-I would also be
predictive in the diagnosis of GHD, and therefore IGF-I was
used as screening instrument in adult childhood cancer survivors.
Our data showed that more than 60% of the 28 survivors that were
tested for GHD turned out to be severely GH deficient, leading us
to conclude that low IGF-I is a useful screening instrument.
Indeed, pathologically low IGF-I levels (below 2 SDS) have
been reported to be a sensitive screening marker, especially in
young adults with severe GHD [26]. However, low IGF-I levels
do not always represent GHD, because IGF-I levels are dependent
upon many other states, such as thyroid function, insulin action,
nutritional status, or chronic disease and, therefore, do not fully
represent GH status [27]. Furthermore, it is known that IGF-I
levels can be artificially normal after CRT treatment because of
neurosecretory dysfunction [27] and therefore, the general
consensus guideline for adult GHD screening prescribes a man-
datory GH stimulation test in cases of clinically suspected GHD
[12].
Previous studies in childhood ALL survivors have shown that
low IGF-I levels associate with high BMI, high total and visceral
fat percentage, and low lean body mass [6,13–14]. BMI is often
used to quantify the level of obesity; however, it is known to be
only a crude indicator of body fat mass [28–31]. High amounts of
total body fat, high visceral fat percentage, and low lean body
mass are more accurate markers for true body composition and
subsequently are more reliable as risk factors for the development
of cardiovascular disease or diabetes mellitus [28–31]. Our study
in a large heterogeneous group of adult childhood cancer survi-
vors, confirms that there is a significant negative correlation be-
tween IGF-I levels and BMI, WHRs and total fat percentage, and
a positive correlation with lean body mass. However, if we focus
on the subgroups that had been treated with cranial irradiation,
IGF-I SDS showed a stronger positive correlation with lean body
mass, whereas, the other measures of body composition were not
correlated with IGF-I SDS. However, the correlation coefficients
were very weak, meaning that only 2–5% of the change in body
composition is explained by low IGF-I levels.
According to the national guidelines of screening for late
effects as implemented by the DCOG, routine measurement of
IGF-I levels was omitted, except in groups that are at high risk for
GHD, that is, CRT treated ALL survivors and locally irradiated
brain tumor survivors [32]. Whereas, low IGF-I levels can guide
us to test for GHD, normal IGF-I levels, especially after CRT
treatment, do not exclude GHD. Therefore, we recommend that
routine IGF-I measurement in these groups be replaced with
regular assessment of an insulin tolerance test, which is the
gold standard test for GHD. Furthermore, because IGF-I is not
a useful marker for clinically relevant alterations in body compo-
sition, DEXA scans are recommended in risk groups, as defined in
the current study, to assess fat mass and lean body mass.
In this large study we evaluated BMI and body composition in
different treatment groups and concluded that after CRT treatment
BMI, total fat percentage, WHR, and visceral fat percentage,
which is a major risk factor for cardiovascular morbidity, were
significantly raised in comparison with not cranially irradiated
survivors. Lean body mass was not significantly different. This
finding is in agreement with earlier smaller studies in ALL sur-
vivors which showed higher BMI, higher total and visceral fat
percentage in CRT survivors, in combination with lower lean
body mass, which was not found in our CRT survivors [13–14].
This is the first study to measure body composition in a large
group of irradiated brain tumor survivors, whereas, most of the
previous studies on body composition are in ALL survivors.
Alterations in body composition were represented by higher total
fat percentage and lower lean body mass, without significantly
higher BMI. Gurney et al. [6] showed that brain tumor survivors
treated with high dose radiotherapy of the hypothalamus had
increased BMI. We did not find raised BMI in irradiated
brain tumor survivors, which might be explained by the fact
that we did not make a distinction between hypothalamic and
non-hypothalamic irradiation.
TABLE III. Adjusted Regression Coefficients (95% CI) of IGF-I Levels and Components of Body Composition of the Different
Radiotherapy Groups Compared to the not Cranially Irradiated Group (n ¼ 452), Adjusted for Possible Confoundersy
Tumor field CRT (42 Gy (35–54)) CRT (25 Gy (24–25)) TBI (8 Gy (8–12))
N ¼ 56 N ¼ 58 N ¼ 21
Height SDS 0.8 (1.2; 0.5) 0.7 (1.1; 0.4) 0.7 (1.3; 0.2)
DTH SDS  height SDS 1.2 (0.8–1.7) 0.8 (0.4–1.2) 1.1 (0.5–1.8)
Body mass index (kg/m2) 3.7 (12.2–8.9) 11.9 (6.8–17.2) 10.2 (16.7; 3)
Waist–hip ratio 0.02 (0 –0.04) 0.04 (0.02 –0.07) 0.02 (0.01–0.06)
Visceral fat percentage (%) 0.2(0.4–0.8) 1.1 (0.6–1.7) 0.8 (0–1.6)
Total fat percentage (%) SDS 0.4 (0.1–0.7) 0.6 (0.3–0.9) 0.4 (0.02–0.9)
Lean body mass (kg) SDS 0.7 (1.2; 0.3) 0.1 (0.5–0.3) 1.6 (2.2; 0.9)
IGF-I SDS 0.9 (1.2; 0.6) 1.2 (1.5; 0.8) 0.2 (0.7–0.4)
IGF-I SDS  1 (OR, 95% CI) 3.2 (1.7–6) 4.3 (2.3–8.2) 1.4 (0.5–4.1)
SDS, standard deviation score; TH, target height; DTH SDS  height SDS difference between target height SDS and height SDS; OR, odds
ratio; CI, confidence interval. P < 0.05. P < 0.001. yRegression coefficient adjusted for sex, age at diagnosis, follow-up time, recurrence,
use of oral contraceptives, and hypogonadism (expressed as testosterone <9 nmol/L (m) or oligo/amenorrhea without OC use (f)). IGF-I SDS
and SD scores are adjusted for all these variables minus sex and follow-up time. Height, body mass index, waist hip ratio, visceral fat
percentage, total fat percentage, and lean body mass are also adjusted for treatment with corticosteroids.
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CONCLUSION
This study shows that IGF-I is not of additional value for
identifying subjects at risk for alterations in body composition.
Patients who had cranial irradiation had higher total fat percent-
age and lower lean body mass than patients not treated with
cranial ı`rradiation.
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